Skip to content
Review Open access

TURNING THE TIDE: BRAF-TARGETED THERAPY ENABLING SURGICAL DOWNSTAGING IN STAGE IVC ANAPLASTIC THYROID CANCER

Oct 2026 · Thyroid Research and Practice · 0 citations

Abstract

Anaplastic thyroid cancer (ATC) constitutes less than 2% of thyroid cancer but accounts for up to 50% of thyroid cancer mortality, with a median survival of 3–6 months. All ATC is Stage IV at diagnosis by definition. BRAF V600E-mutant disease is the only molecularly defined subset with FDA-approved targeted therapy (dabrafenib–trametinib). We report a case in which BRAF-directed therapy enabled curative-intent surgery in a patient with Stage IVC disease. A 68-year-old woman presented with a rapidly enlarging right thyroid mass, facial plethora and internal jugular vein thrombosis. Core biopsy and immunohistochemistry confirmed ATC; next-generation sequencing revealed a BRAF V600E, TERT promoter and TP53 “triple-hit” signature arising from a dedifferentiated papillary carcinoma. PET-CT showed an FDG-avid primary, nodal disease and bilateral lung metastases (Stage IVC). She received palliative external beam radiotherapy and chemotherapy, followed by dabrafenib plus trametinib, achieving a 70% partial response with resolution of nodal and pulmonary disease. Disease progression eight months later prompted addition of pembrolizumab, complicated by immune-related granulomatous panniculitis requiring discontinuation. Multidisciplinary review subsequently confirmed an isolated thyroid remnant with no residual nodal or distant disease, permitting total thyroidectomy with bilateral neck dissection. Histopathology confirmed unifocal ATC with 40% treatment response, a 1 mm ancestral papillary carcinoma focus, and involved margins; disease was restaged as ypT3bN1a (Stage IVA). The patient is euthyroid on levothyroxine, receiving adjuvant radiotherapy, with BRAF-targeted therapy to resume thereafter with three-monthly surveillance imaging. This case shows that BRAF-directed dual MAPK blockade can downstage unresectable, metastatic ATC to resectable disease, transforming outcomes in a malignancy once regarded as fatal. Early BRAF testing and multidisciplinary care are essential to enable this therapeutic paradigm shift.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.